China Universal Asset Management Company’s Monte Rosa Therapeutics GLUE Stock Holding History

China Universal Asset Management Company’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$223K	Sell	13,530 -5,081	-27%	-$97.2K	0.02%	344
2025 Q4	$292K	Sell	18,611 -12,214	-40%	-$165K	0.02%	310
2025 Q3	$228K	Sell	30,825 -1,529	-5%	-$8.1K	0.02%	323
2025 Q2	$146K	Buy	32,354 +20,031	+163%	+$89.3K	0.01%	336
2025 Q1	$57.2K	Sell	12,323 -704	-5%	-$4.32K	0.01%	409
2024 Q4	$90.4K	Buy	+13,027	New	+$97.8K	0.01%	407
2023 Q4	–	Sell	-1,280	Closed	-$6.13K	–	450
2023 Q3	$6.13K	Buy	1,280 +633	+98%	+$4.08K	﹤0.01%	379
2023 Q2	$4.43K	Sell	647 -9	-1%	-$58	﹤0.01%	382
2023 Q1	$5.11K	Buy	656 +164	+33%	+$1.14K	﹤0.01%	364
2022 Q4	$3.74K	Buy	492 +55	+13%	+$458	﹤0.01%	331
2022 Q3	$4K	Buy	+437	New	+$4.01K	﹤0.01%	298

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

China Universal Asset Management Company's GLUE Position: Q1 2026 in Review

China Universal Asset Management Company reduced its Monte Rosa Therapeutics (GLUE) stake by 27% in Q1 2026, selling an estimated $97.2K and leaving 13,530 shares worth $223K. The position accounts for 0.02% of the portfolio, ranked #344.

China Universal Asset Management Company first reported a position in GLUE in Q3 2022 and has held it in 11 quarters since. The position peaked at $292K in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

China Universal Asset Management Company held 13,530 shares of Monte Rosa Therapeutics worth $223K as of Q1 2026.
China Universal Asset Management Company sold 5,081 Monte Rosa Therapeutics shares in Q1 2026, an estimated $97.2K.
Monte Rosa Therapeutics made up 0.02% of China Universal Asset Management Company's portfolio in Q1 2026, its #344 holding.
China Universal Asset Management Company first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 11 quarters since.
China Universal Asset Management Company's Monte Rosa Therapeutics position peaked at $292K in Q4 2025.
190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.